Max-planck-gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

The University of Chicago

Technische Universitat Munchen

Other

Bruker Daltonik Gmbh

Atlas Antibodies Ab

Der Wissenschaft En E.v.

Bruker Daltonics Gmbh & Co. Kg

Mann, Matthias

Matthias Mann

Felix Meissner

Bernhard K Mueller

Markus Gerhard

Philippe Patrick Monnier

Ernst Lengyel

Paolo Macchi

Friedrich Bonhoeffer

Bernd Stahl

Nils A Kulak

Daniel Hornburg

Tobias Kruse

Fabian Coscia

Marion Curtis

Melvin Andrew Park

Oliver Räther

Mathias Uhlén

Markus Lubeck

Bernhard Singer

Florian Meier

Arturo Zychlinsky

Sebastian Virreira Winter

Garwin Pichler

Steffen Backert

Han Remaut

Anahita Javaheri

Jens S Anderson

Jens S Andersen

Werner Lothar Straube

Jacek R Wisniewski

Jürgen Cox

Francesca Forner

Tamar Geiger

Emma Lundberg

Marlis Zeiler

Nagarjuna Nagaraj

Seyed Babak Azimifar

Bernhard B Singer

Mel Park

Werner Straube

The current disclosure relates to methods for treating ovarian cancer based on specific antigen expression of the cancer. Furthermore, the expressed antigen may be used in immunotherapeutic methods for treatment of the ovarian cancer. Aspects of the disclosure relate to immunotherapies targeting CT45 polypeptides, methods for treating ovarian cancer based on CT45 expression, and kits for detecting CT45 polypeptides and nucleotides.

Methods of treating cancers with CT45 targeted therapies

The present invention relates to a method of purifying peptides and/or polypeptides, said method comprising or consisting of: (a) loading a sample comprising peptides and/or polypeptides under acidic or neutral aqueous conditions on mixed-phase solid phase extraction (SPE) material, wherein said material consists of or comprises reversed phase/ion exchange material; (b) washing said mixed-phase SPE material with (ba) an acidic or neutral composition comprising at least 50% (v/v) organic solvent; and/or (bb) an acidic or neutral aqueous solution; and (c) eluting said peptides and/or polypeptides from said mixed-phase SPE material with an alkaline composition comprising at least 50% (v/v) organic solvent.

Peptide purification using mixed-phase solid phase extraction material

The present invention relates to inhibitors of the interaction betweenIIopQ and a member of the carcinoembryonic antigen-related cell adhesion molecule (CEACAM) family as well as to immunogenic compositions based onHopQ. The present invention further relates to the use of the inhibitors and immunogenic compositions for preventing or treating a disease or disorder caused by or associated with

Methods for treatment ofinfections

The present invention relates to use of an isobaric label in mass spectrometry (MS) analysis using data-independent acquisition (DIA), wherein said isobaric label comprises or consists of a group which fragments in the mass spectrometer (i) at an energy below the energy required for fragmenting analyte-derived precursor ions and/or a higher conversion rate than said precursor ions; and (ii) at said energy according to (i) and when coupled to a precursor ion, at a single site within said group, to yield a first moiety and a second moiety, said second moiety being coupled to said precursor ion.

Uses of isobaric tags in mass spectrometry

The present invention relates to immunogenic compositions and their use in the prevention or treatment of diseases or disorders caused by or associated with, in particularinfection and gastroduodenal disorders caused by. The present invention further relates to methods of detectinginfection in a subject.

vaccines

The invention provides a method for acquiring fragment ion spectra of substances in complex substance mixtures wherein a trapped ion mobility spectrometer ('TIMS') is used as the ion mobility separator separation device. The fragment ion spectra may be used for the identification of high numbers of proteins in complex mixtures, or for a safe quantification of some substances, by their fragment ion mass spectra in a mass spectrometer with up-front substance separator. TIMS with parallel accumulation provides the unique possibility to prolong the ion accumulation duration to find more detectable ion species without decreasing the measuring capacity for fragment ion mass spectra. The high measurement capacity for fragment ion mass spectra permits the repeated measurement of low abundance ion species to improve the quality of the fragment ion spectra.

Acquisition of fragment ion mass spectra of ions separated by their mobility

Disclosed is a sample preparation container for purification and/or enrichment of bio-organic compounds from cellular material, viruses and/or sub-components of these. The container includes a reaction chamber and a chromatography medium. The reaction chamber is for holding the cellular material, etc. and is configured to perform reactions inside. The chromatography medium is configured to purify the bio-organic compounds. The chromatography medium is located at a wall of the reaction chamber, and the wall is closed or sealed and configured to be opened for obtaining purified bio-organic compounds. The sample preparation container further includes a receiving chamber for receiving the bio-organic compounds, that is adjacent to the chromatography medium such that the chromatography medium separates the reaction chamber from the receiving chamber. The outer face of the receiving chamber is closed and configured to be opened for obtaining purified bio-organic compounds.

Reaction vessel for sample preparation

This invention relates to a method of determining the absolute amount of a target polypeptide in a sample using mass spectrometry.

Quantitative standard for mass spectrometry of proteins

The present invention relates to a method that allows comprehensive quantitation of one or a plurality biomolecules, including the entire complement of biomolecules in a sample by comparing their quantity to the quantity of reference biomolecules in a standard mixture obtained via extraction from at least two different cell populations. The invention further relates to said standard mixture itself, its preparation and use.

Method for quantifying biomolecules

The present invention relates to the use of a modulator of a polypeptide having or comprising an amino acid sequence as disclosed herein or of a functional fragment or derivative thereof or of a polynucleotide encoding said polypeptide or fragment or derivative for the preparation of a pharmaceutical composition for preventing, alleviating or treating diseases or conditions associated with the degeneration or injury of vertebrate nervous tissue, associated with seizures or associated with angiogenic disorders or disorders of the cardio-vascular system.

Use of RGM and its modulators

The present invention relates to the use of a modulator of a polypeptide having or comprising an amino acid sequence as disclosed herein or of a functional fragment or derivative thereof or of a polynucleotide encoding said polypeptide or fragment or derivative for the preparation of a pharmaceutical composition for preventing, alleviating or treating diseases or conditions associated with the degeneration or injury of vertebrate nervous tissue, associated with seizures or associated with angiogenic disorders or disorders of the cardio-vascular system. Furthermore, the invention provides for the use of a modulator of a polypeptide having or comprising said amino acid sequence of a functional fragment or derivative thereof or of a polynucleotide encoding said polypeptide or fragment or derivative for the preparation of a pharmaceutical composition for preventing, alleviating or treating diseases or conditions associated with the degeneration or injury of vertebrate nervous tissue, associated with angiogenic disorders or disorders of the cardio-vascular system. In addition the invention provides for the use of said polypeptide or said functional fragment or derivative thereof for the preparation of a pharmaceutical composition for preventing or treating tumor growth or formation of tumor metastases or as a marker of stem cells.

Therapeutic use of antibodies directed against repulsive guidance molecule (RGM)

Growing community of inventors

Stockdorf, Germany

Matthias Mann